BioMimics 3D Stent Clinical Investigation: The Mimics Study

Not Applicable

Completed

• Conditions: Peripheral Arterial Disease
• Interventions: Device: Femoropopliteal stenting

• Registration Number: NCT02163863
• Lead Sponsor: Veryan Medical Ltd.

Brief Summary

Primary purpose of the Mimics Study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease.

Detailed Description

The Mimics Study is a prospective, part randomized study; an initial roll-in registry of 10 subjects treated with BioMimics 3D followed by a randomized assignment to treatment with BioMimics 3D or Control on a 2:1 basis for 76 subjects.

The primary purpose of the study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease based on:

* Safety; measured by freedom from major adverse events determined at 30 days after the procedure, compared to historic controls.

* Performance; measured by freedom from clinically driven TLR at 6 months, compared to historic controls.

Study Timeline

• Study Start: 2010-02
• Primary Completion: 2012-10
• Study First Submitted: 2014-06-09
• Study First Submitted QC: 2014-06-13
• Study First Posted: 2014-06-16
• Study Completion: 2014-07
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-12
• Last Update Posted: 2019-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

• >18 years of age
• The subject or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent
• The subject is willing to be available for the appropriate follow-up for the duration of the study
• Rutherford 1-4(mild claudication to ischemic rest pain), with an occlusion or de novo and/or restenotic SFA/PPA lesion ≥50% and ABI/TBI <0.90/0.80
• Single target lesion located at least 1 cm distal to the take-off of the profunda femoris artery and at least 3 cm proximal to the highest point of the cortical margin of the femur
• Target vessel reference diameter is ≥3.5 mm and ≤7.0 mm
• Target lesion length is ≥4.0 cm and ≤10.0 cm, and must be intended to be covered with one single stent only. A second stent is permitted to be placed only if, in the physician's opinion, the first stent did not achieve an optimum clinical result
• Adequate distal run-off to the ankle in the target limb (defined as having at least one patent calf vessel <50% stenosed
• Life expectancy >24 months

Exclusion Criteria

• Women who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment (if not already post menopausal) or women who do not agree to use an adequate birth control method for up to 24 months after Device implantation
• An uncontrolled infectious disease
• A condition that inhibits radiographic visualisation of the arteries
• Any condition that precludes safe access with PTA devices, such as: excessive common femoral artery disease, unresolved fresh thrombus in the target lesion/vessel, or a target lesion/vessel that is excessively tortuous or calcified
• Known allergy to, or intolerance of, Nitinol
• Known intolerance of aspirin and/or clopidogrel
• Known hypersensitivity to contrast media which cannot be pre-treated
• Participation in another device or drug study. Subject must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this study. The subject may only be enrolled in this study once
• The subject is unable and/or unwilling to cooperate with study procedures or required follow-up visits
• History of bleeding diatheses or coagulopathy or will refuse blood transfusions
• Known impaired renal function, defined as creatinine >2.5 mg/dl except subjects under chronic renal replacement therapy
• Known platelet count <80,000 cells/mm3 or >700,000 cells/mm3
• Known WBC of <3,000 cells/mm3
• The subject is unable to bend lower limbs (full knee flexion) and/or has a knee prosthesis
• Previous treatment of the target lesion 6 months prior to enrollment; previous femoropopliteal bypass in the target vessel; previous stenting of the target lesion
• Previous stenting of the SFA, popliteal and tibial arteries within the target limb
• Target lesion located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion
• Target lesion requires treatment other than standard PTA prior to stent placement (i.e., no other devices or procedures such as cutting balloons and laser atherectomy are permitted to be used during the index procedure)
• Lesions in contralateral SFA that require intervention during the index procedure, or within 30 days after the index procedure, unless both limbs are able to be and are included in the study
• Multiple lesions in the target vessel that require stenting within 30 days after study procedure
• Target lesion length is > 10cm or the physician believes prior to stent placement that the lesion cannot be covered by one single stent
• The target lesion is severely calcified

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Femoropopliteal stenting	CR Bard LifeStent System, delivering a self-expanding Nitinol stent
BioMimics 3D	Femoropopliteal stenting	The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.

Primary Outcome Measures

Name	Time	Method
Primary safety endpoint	30 days	Freedom from major adverse events defined as death, amputation and target lesion revascularization (TLR)
Primary performance endpoint	6 months	Freedom from clinically driven TLR

Secondary Outcome Measures

Name	Time	Method
Acute procedural outcomes	Within 30 days of the procedure	* Device deployment success; * Acute procedural success; * Procedural complications
Post implant anatomical outcomes	Immediately post implant but within the index procedure	- Stented vessel geometry, i.e. presence/absence of 3D helical geometry in the stented region
Mechanical outcomes	30 days, 6, 12 and 24 months	- Stent integrity, i.e. presence/absence of kinks and fractures
Haemodynamic outcomes	discharge, 30 days, 6, 12 and 24 months	* Restenosis measured by duplex ultrasound and angiography.; * Swirling flow
Clinical and functional outcomes	discharge, 30 days, 6, 12 and 24 months	* Rutherford classification (not at discharge); * ABI; * Walking impairment questionnaire (not at discharge); * Freedom from major adverse events at 30 days, 6, 12 and 24 months.

Trial Locations

Locations (1)

Universitaets-Herzzentrum Freiburg-Bad Krozingen; 🇩🇪 Bad Krozingen, Germany